BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9887242)

  • 21. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma urocortin levels in the diagnosis of ovarian endometriosis.
    Florio P; Reis FM; Torres PB; Calonaci F; Toti P; Bocchi C; Linton EA; Petraglia F
    Obstet Gynecol; 2007 Sep; 110(3):594-600. PubMed ID: 17766605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Benign ovarian tumor with ascites and high serum levels of CA125: report of 3 cases].
    Li HJ; Shen K; Lang JH; Wu M; Huang HF; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):147-9. PubMed ID: 12816688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.
    Ott HW; Lindner H; Sarg B; Mueller-Holzner E; Abendstein B; Bergant A; Fessler S; Schwaerzler P; Zeimet A; Marth C; Illmensee K
    Cancer Res; 2003 Nov; 63(21):7507-14. PubMed ID: 14612552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
    Wahlberg K; Høyer-Hansen G; Casslén B
    Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normal interleukin-10 serum level opposed to high serum levels of carbohydrate antigen 19-9 and cancer antigens 125 and 50 in a case of true splenic cyst.
    Lieto E; Castellano P; Ferraraccio F; Orditura M; De Vita F; Romano C; Pignatelli C; Galizia G
    Arch Med Res; 2003; 34(2):145-8. PubMed ID: 12700012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.
    Koivunen E; Itkonen O; Halila H; Stenman UH
    Cancer Res; 1990 Apr; 50(8):2375-8. PubMed ID: 2180568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential diagnosis of peri- and postmenopausal ovarian cysts.
    Reimer T; Gerber B; Müller H; Jeschke U; Krause A; Friese K
    Maturitas; 1999 Jan; 31(2):123-32. PubMed ID: 10227005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas.
    Ivarsson K; Ekerydh A; Fyhr IM; Janson PO; Brännström M
    Acta Obstet Gynecol Scand; 2000 Sep; 79(9):777-84. PubMed ID: 10993102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of biochemical markers between benign and malignant ovarian cysts.
    Knight JA; Wu JT; Miya T; Knight DP
    Clin Physiol Biochem; 1986; 4(2):130-5. PubMed ID: 3516514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The copper concentration in the blood serum of women with ovarian tumors (a preliminary report)].
    Marinov B; Tsachev K; Doganov N; Dzherov L; Atanasova B; Markova M
    Akush Ginekol (Sofiia); 2000; 39(2):36-7. PubMed ID: 10948620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA ploidy of ovarian and adnexal cyst fluid. A useful adjunct to cytology.
    Greenebaum E; Yee HT; Liu J
    Acta Cytol; 1994; 38(2):201-8. PubMed ID: 8147211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
    Candido Dos Reis F; Moreira de Andrade J; Bighetti S
    Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours.
    Haeger M; Swahn M; Hahlin M; Horvath G; Bengtsson A
    Anticancer Res; 1996; 16(5B):3189-92. PubMed ID: 8967734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
    Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ovarian cysts: strategy and prognosis].
    Querleu D; Parmentier D; Chevallier L
    Contracept Fertil Sex; 1993 Feb; 21(2):167-72. PubMed ID: 7951609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.